Nandrolone and trenbolone belong to the 19-nortestosterone (19-nor) family, and they carry a side-effect profile that pure testosterone does not: problems tied to progesterone and prolactin. Because the fixes for these are completely different from the fixes for estrogen, confusing the two is a common and frustrating mistake. This guide separates them.
Why 19-nors are different A 19-nor is testosterone with the carbon-19 methyl group removed. That small change gives these compounds meaningful progestogenic activity — they interact with the progesterone receptor. Progesterone-driven signalling can, in turn, raise prolactin and sensitise breast tissue to whatever estrogen is around. This is why 'nandrolone gyno' and 'tren gyno' can appear even when serum estradiol looks controlled: the driver is partly progestogenic, not purely estrogenic. Nandrolone also aromatizes (at a lower rate than testosterone), while trenbolone does not aromatize at all — a fact that trips people up, because tren users still get gyno-like and libido problems despite tren producing no estrogen itself.
Prolactin sides versus estrogen sides The symptom sets overlap but the signatures differ: - Prolactin excess tends to show up as low libido, difficulty reaching orgasm, erectile problems, and in some cases a milky nipple discharge (galactorrhoea). Water retention is not its calling card. - Estrogen excess tends to show up as bloating and puffiness, emotional lability, and tender gyno. - The tell: if you are on a 19-nor, your estradiol is in range, and your libido has collapsed or you have nipple discharge, think prolactin/progesterone — not estrogen. Reaching for an aromatase inhibitor at that point can make things worse by dragging estrogen too low on top of the existing problem.
A useful nuance from the clinical literature: prolactin is often blamed for everything, but the progestogenic activity of these compounds is itself a direct contributor to libido and erectile complaints, independent of how high prolactin actually reads. So a normal prolactin result does not fully exonerate a 19-nor. Measure prolactin if symptoms appear, but do not assume a normal value means the 19-nor is blameless.
Dopamine agonists: cabergoline and pramipexole Prolactin release is held in check by dopamine, so the pharmacological lever for high prolactin is a dopamine agonist. Two are used off-label: - Cabergoline is a long-acting dopamine agonist, dosed roughly 0.25-0.5 mg once or twice weekly in this context. It is effective at lowering prolactin and is generally better tolerated than older agents. The serious caution comes from Parkinson's and prolactinoma medicine: high, chronic doses of ergot-derived agonists like cabergoline are associated with cardiac valve fibrosis. The doses used by athletes are far lower than those linked to valvulopathy, but the signal is real and argues against casual, indefinite use. - Pramipexole is a non-ergot dopamine agonist, so it does not carry the valve-fibrosis concern. It is shorter-acting, more prone to nausea and next-day grogginess, and is usually taken at night.
Both can cause nausea, dizziness, low blood pressure and, at higher doses, impulse-control effects. They are not something to run prophylactically 'just in case' — use them to treat a demonstrated problem.